PACB Earnings & Financial Statements
Pacific Biosciences of California, Inc.
$1.99
-$0.06(-2.93%)
52
Overall
40
Value
75
Tech
42
Quality
Market Cap
$618.55M
Volume
9.14M
52W Range
$1.07 - $3.44
Target Price
$2.14
PACB earnings and financial statements: Pacific Biosciences of California, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
PACB Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $160.00M | $154.01M | $200.52M | $128.30M | $130.51M |
| Cost of revenue | - | - | $3.44M | $3.71M | $71.65M |
| Operating income | -$553.86M | -$474.31M | -$334.47M | -$307.20M | -$210.44M |
| EBITDA | -$152.69M | -$242.77M | -$277.28M | -$281.51M | -$250.76M |
| Net income | -$546.38M | -$309.85M | -$306.74M | -$314.25M | -$181.22M |
| EPS (diluted) | $-1.82 | $-1.59 | $-1.21 | $-1.40 | $-0.89 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $784.08M | $1.26B | $1.75B | $1.77B | $2.01B |
| Total liabilities | $778.73M | $753.85M | $1.04B | $1.20B | $1.22B |
| Shareholders’ equity | $5.35M | $506.59M | $701.30M | $562.90M | $790.99M |
| Cash and equivalents | $63.71M | $55.37M | $179.91M | $325.09M | $460.73M |
| Long-term debt | $701.97M | $662.41M | $923.85M | $937.75M | $946.04M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$111.21M | -$206.06M | -$259.17M | -$263.21M | -$111.18M |
| Capital expenditure | -$7.71M | -$6.19M | -$8.84M | -$16.93M | -$5.93M |
| Free cash flow | -$118.92M | -$212.25M | -$268.02M | -$280.14M | -$117.11M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PACB | $1.99 | -2.9% | 9.14M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Pacific Biosciences of California, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW